cefcapene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 4159 135889-00-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefcamate
  • cefcapene
  • Molecular weight: 453.49
  • Formula: C17H19N5O6S2
  • CLOGP: -0.38
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 4
  • TPSA: 177.94
  • ALOGS: -4.07
  • ROTB: 8

Drug dosage:

DoseUnitRoute
0.45 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.482 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.230 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.519 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 1.820 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 55.110 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 42.520 % Moderate 0.65
herg hERG pIC50 4.212 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 2.218 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 3.990 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 37.490 % Moderate 0.65
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MARK4,MTOR,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK 49
kinase-selectivity-class ACVR2B,AXL,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK12,MAPK7,PRKDC,STK33,TEK,TGFBR1,TTK 17
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.989 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 4.699 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 51.670 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.253 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 35.200 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 1.563 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.470 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 38.030 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 972.747 uM Moderate 0.65

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DD17 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01DD Third-generation cephalosporins 17 drugs
cefdinircefditoren pivoxilcefetametcefiximecefmenoximecefodizimecefoperazonecefotaximecefpiramidecefpodoxime proxetilcefsulodinceftazidime show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.32 acidic
pKa2 13.88 acidic
pKa3 3.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D07638 KEGG_DRUG
C2699134 UMLSCUI
CHEBI:131729 CHEBI
CHEMBL582912 ChEMBL_ID
DB13461 DRUGBANK_ID
12053 IUPHAR_LIGAND_ID
7006 INN_ID
4D5D3422MW UNII
6436055 PUBCHEM_CID
4D5D3422MW INXIGHT DRUGS

Pharmaceutical products:

None